OCT生物标志物与DME患者抗VEGF治疗预后的相关性
Correlation between OCT Biomarkers and Prognosis of Anti-VEGF Therapy in Patients with DME
摘要: 糖尿病黄斑水肿(DME)在全球范围内严重威胁患者视力。抗VEGF治疗是目前DME的一线治疗方式，部分患者对这一治疗方式反应较差，有研究发现，某些OCT生物标志物与抗VEGF治疗不应答有一定的相关性。本文从DME的发病机制，抗VEGF治疗原理及OCT生物标志物与抗VEGF治疗的相关性展开描述，分析DME患者的OCT特征，指导诊断及治疗。
Abstract: Diabetic macular edema (DME) is a serious threat to visual acuity worldwide. Anti-VEGF therapy is the current first-line treatment for DME, and some patients have poor response to this treatment. Some studies have found that some OCT biomarkers are associated with non-response to anti-VEGF therapy. In this paper, the pathogenesis of DME, the principle of anti-VEGF therapy and the correla-tion between OCT biomarkers and anti-VEGF therapy were described, and the OCT features of DME patients were analyzed to guide diagnosis and treatment.
文章引用：文丹丹, 王理论. OCT生物标志物与DME患者抗VEGF治疗预后的相关性[J]. 临床医学进展, 2023, 13(4): 5093-5099. https://doi.org/10.12677/ACM.2023.134722

参考文献

[1] Ogurtsova, K., Da Rocha Fernandes, J.D., Huang, Y., et al. (2017) IDF Diabetes Atlas: Global Estimates for the Preva-lence of Diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 128, 40-50. [Google Scholar] [CrossRef] [PubMed]
[2] Munk, M.R., Somfai, G.M., de Smet, M.D., et al. (2022) The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. International Journal of Mo-lecular Sciences, 23, 7585. [Google Scholar] [CrossRef] [PubMed]
[3] Parravano, M., Costanzo, E. and Querques, G. (2020) Profile of Non-Responder and Late Responder Patients Treated for Diabetic Macular Edema: Systemic and Ocular Factors. Acta Diabetologica, 57, 911-921. [Google Scholar] [CrossRef] [PubMed]
[4] 史雪辉, 张丛, 魏文斌. 关注糖尿病黄斑水肿的光学相干断层扫描分型及相关影像特征[J]. 中华眼科医学杂志(电子版), 2021, 11(1): 1-7.
[5] Vujosevic, S., Toma, C., Villani, E., et al. (2020) Diabetic Macular Edema with Neuroretinal Detachment: OCT and OCT-Angiography Biomarkers of Treatment Response to Anti-VEGF and Steroids. Acta Diabetologica, 57, 287-296. [Google Scholar] [CrossRef] [PubMed]
[6] Sun, J.K., Lin, M.M., Lammer, J., et al. (2014) Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes with Center-Involved Diabetic Macular Edema. JAMA Ophthalmology, 132, 1309-1316. [Google Scholar] [CrossRef] [PubMed]
[7] Hammes, H.P. (2018) Diabetic Retinopathy: Hypergly-caemia, Oxidative Stress and Beyond. Diabetologia, 61, 29-38. [Google Scholar] [CrossRef] [PubMed]
[8] Brownlee, M. (2001) Biochemistry and Molecular Cell Biology of Diabetic Complications. Nature, 414, 813-820. [Google Scholar] [CrossRef] [PubMed]
[9] Diabetic Retinopathy Clinical Research Network; Wells, J.A., Glassman, A.R. and Ayala, A.R. (2015) Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. The New England Journal of Medicine, 372, 1193-1203. [Google Scholar] [CrossRef] 
[10] Bressler, N.M., Varma, R., Suñer, I.J., et al. (2014) Vision-Related Function after Ranibizumab Treatment for Diabetic Macular Edema: Results from RIDE and RISE. Ophthalmology, 121, 2461-2472. [Google Scholar] [CrossRef] [PubMed]
[11] Ehlers, J.P., Yeh, S. and Maguire, M.G. (2022) Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. Ophthalmology, 129, 88-99. [Google Scholar] [CrossRef] [PubMed]
[12] Haritoglou, C., Maier, M., Neubauer, A.S., et al. (2020) Current Concepts of Pharmacotherapy of Diabetic Macular Edema. Expert Opinion on Pharmacotherapy, 21, 467-475. [Google Scholar] [CrossRef] [PubMed]
[13] Browning, D.J., Stewart, M.W. and Lee, C. (2018) Diabetic Macular Edema: Evidence-Based Management. Indian Journal of Ophthalmology, 66, 1736-1750. [Google Scholar] [CrossRef] 
[14] Roh, M.I.M., Kim, H.S.M., Song, J.H.M., et al. (2009) Effect of In-travitreal Bevacizumab Injection on Aqueous Humor Cytokine Levels in Clinically Significant Macular Edema. Oph-thalmology (Rochester, Minn.), 116, 80-86. [Google Scholar] [CrossRef] [PubMed]
[15] Dysli, M., Ruckert, R. and Munk, M.R. (2019) Differentiation of Underlying Pathologies of Macular Edema Using Spectral Domain Optical Coherence Tomography (SD-OCT). Ocular Immunology and Inflammation, 27, 474-483. [Google Scholar] [CrossRef] [PubMed]
[16] Ceklic, L., Huf, W., Ebneter, A., et al. (2019) The Impact of Ganglion Cell Layer Cysts in Diabetic Macular Oedema Treated with Anti-Vascular Endothelial Growth Factor. Acta Ophthalmologica (Oxford, England), 97, e1041-e1047. [Google Scholar] [CrossRef] [PubMed]
[17] Yanoff, M., Fine, B.S., Brucker, A.J., et al. (1984) Pathology of Human Cystoid Macular Edema. Survey of Ophthalmology, 28, 505. [Google Scholar] [CrossRef] [PubMed]
[18] Karst, S.G., Lammer, J. and Mitsch, C. (2018) Detailed Anal-ysis of Retinal Morphology in Patients with Diabetic Macular Edema (DME) Randomized to Ranibizumab or Triamcino-lone Treatment. Graefe’s Archive for Clinical and Experimental Ophthalmology, 256, 49-58. [Google Scholar] [CrossRef] [PubMed]
[19] Zur, D., Iglicki, M., Sala Puigdollers, A., et al. (2019) Disorgani-zation of Retinal Inner Layers as a Biomarker in Patients with Diabetic Macular Oedema Treated with Dexamethasone Implant. Acta Ophthalmologica, 98, e217-e223. [Google Scholar] [CrossRef] [PubMed]
[20] Chan, E.W., Eldeeb, M. and Sun, V. (2019) Disorganization of Retinal In-ner Layers and Ellipsoid Zone Disruption Predict Visual Outcomes in Central Retinal Vein Occlusion. Ophthalmology Retina, 3, 83-92. [Google Scholar] [CrossRef] [PubMed]
[21] Framme, C., Schweizer, P., Imesch, M., et al. (2012) Behavior of SD-OCT-Detected Hyperreflective Foci in the Retina of Anti-VEGF-Treated Patients with Diabetic Macular Edema. In-vestigative Ophthalmology & Visual Science, 53, 5814-5818. [Google Scholar] [CrossRef] [PubMed]
[22] Bonfiglio, V., Reibaldi, M., Pizzo, A., et al. (2019) Dexamethasone for Unresponsive Diabetic Macular Oedema: Optical Coherence Tomography Biomarkers. Acta Ophthalmologica (Oxford, England), 97, e540-e544. [Google Scholar] [CrossRef] [PubMed]
[23] Uji, A., Murakami, T., Nishijima, K., et al. (2012) Association between Hyperreflective Foci in the Outer Retina, Status of Photoreceptor Layer, and Visual Acuity in Diabetic Macular Edema. American Journal of Ophthalmology, 153, 710-717. [Google Scholar] [CrossRef] [PubMed]
[24] Castro-Navarro, V., Monferrer-Adsuara, C. and Navarro-Palop, C. (2021) Effect of Dexamethasone Intravitreal Implant on Visual Acuity and Foveal Photoreceptor Integrity in Macular Edema Secondary to Retinal Vascular Disease. Ophthalmologica, 244, 83-92. [Google Scholar] [CrossRef] [PubMed]
[25] Wirth, M.A., Wons, J., Freiberg, F.J., et al. (2018) Impact of Long-Term Intravitreal Anti-Vascular Endothelial Growth Factor on Preexisting Microstructural Alterations in Diabetic Macular Edema. Retina (Philadelphia, Pa.), 38, 1824-1829. [Google Scholar] [CrossRef] 
[26] Seo, K.H., Yu, S., Kim, M., et al. (2016) Visual and Mor-phologic Outcomes of Intravitreal Ranibizumab for Diabetic Macular Edema Based on Optical Coherence Tomography Patterns. Retina (Philadelphia, Pa.), 36, 588-595. [Google Scholar] [CrossRef] 
[27] Iacono, P., Parodi, M.B., Scaramuzzi, M., et al. (2017) Morphological and Functional Changes in Recalcitrant Diabetic Macular Oedema after Intravitreal Dexamethasone Im-plant. British Journal of Ophthalmology, 101, 791-795. [Google Scholar] [CrossRef] [PubMed]
[28] Hatz, K., Ebneter, A., Tuerksever, C., et al. (2018) Re-peated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. Ophthalmologica, 239, 205-214. [Google Scholar] [CrossRef] [PubMed]

为你推荐